Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report

INTRODUCTION: It has been well reported that non-small-cell lung cancer (NSCLC) patients with single epithelial growth factor receptor (EGFR) activating mutation have high objective response rate when treated with EGFR-TKIs. However, due to rarity of cases, the response of patients with EGFR double...

Descripción completa

Detalles Bibliográficos
Autores principales: Bie, Yanan, Wang, Jin, Xiong, Linmin, Wang, Dong, Liao, Jing, Zhang, Yelin, Lin, Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982146/
https://www.ncbi.nlm.nih.gov/pubmed/33725945
http://dx.doi.org/10.1097/MD.0000000000024793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982146/
https://www.ncbi.nlm.nih.gov/pubmed/33725945
http://dx.doi.org/10.1097/MD.0000000000024793

Ejemplares similares